Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 9/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356199 | 0.90 | TACR2 (0.42) | TACR2 | |
| SCHEMBL3361023 | 0.82 | USP2 (0.36) | TACR2HRH2HRH1 | |
| SCHEMBL3360405 | 0.82 | SIRT2 (0.41) | CTSKCAPN1CAPN2CTSSSIRT1 | |
| SCHEMBL3355433 | 0.78 | ACKR3 (0.52) | TACR2CAPN1CAPN2HRH2HRH1 | |
| SCHEMBL3355427 | 0.78 | ACKR3 (0.52) | TACR2CAPN1CAPN2HRH2HRH1 | |
| SCHEMBL27604380 | 0.71 | SIGMAR1 (0.32) | — | |
| SCHEMBL3356191 | 0.67 | ACKR3 (0.51) | TACR2CTSKHRH2HRH1CTSS | |
| SCHEMBL3356195 | 0.67 | ACKR3 (0.51) | TACR2CTSKHRH2HRH1CTSS | |
| SCHEMBL27586599 | 0.65 | KDM4E (0.35) | — | |
| SCHEMBL13496161 | 0.64 | CAPN1 (0.55) | CTSKCAPN1CAPN2CTSSSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | APP, BACE1, IAPP | UTS2R 1650/4885TACR2 2761/4885CTSK 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.